Epstein Secrets

Chart lee 90 — 72 PriceIS) es 36—' Is - 0 rice charts, are available for compendium reports and

f this report. Investors should consider this report as only a single factor in making their investment decision. EFTA00306883 Chris Schott. CFA North America Equity Research (1-212) 622-5676 02 June 2010 J.P.Morgan Investment Thesis, Valuation and Risks Merck & Co., Inc. (Overweight: Price Target: $64.00) Investment

isclosures: Ira Important disclosures, includin rice charts, are available for compendium reports and

alcolm Barr, Senior European Economist; • Pavan Wadhwa, Global Head of Interest Rate Strategy, Nikolaos Panigirtzoglou, Global Market Strategist. North America Equity Research 26 June 2012 Portfolio Strategy Thomas J Lee, CPAAc J.P. Morgan Securities LLC hor J.P. Morgan Secunties LLC Economic and Policy Research Malc

09 ii 12 14 Sourco. Bloomberg and t Wigan. rice data **Nod lot stook sots and d/..409nds. Brook

tors should consider this report as only a single factor in making their investment decision. www.jpmorganmarkets.com EFTA00301312 Kevin Milota North America Equity Research 13 May 2014 J.P.Morgan Analyst Certification: The research analyst(s) denoted by an "AC" on the cover of this report certifies (or, where multiple

gy and risks msaciated with covered com zanies or rice targets for covered companies, please see the mo

n I/O compounds (GITR), BACE-inhibitor (Alzheimer's) and anaceptrapib (CETP), none of which appear to be reflected in Merck's current share price. North America Equity Research 02 October 2015 Pharmaceuticals — Major & Specialty Chris Schott, CFA AC (1-212)622-5676 Bloomberg JPMA SCHOTT <GO, Aditl Singhania, PhD (1-212

ific Disclosures: Important disclosures includin rice charts, are available for compendium reports and

J.P. Morgan North America Equity Research 24 April 2014 Boeing Company Q1 Encouraging on Several Fronts; Raising Estimates and Price Target Q1 contained several positive developments: 1)